As­traZeneca gains a speedy Imfinzi re­view in race to beat Roche on front­line SCLC

Well, Roche’s Tecen­triq had a good few-month run as the lone front­line im­munother­a­py on the small-cell lung can­cer mar­ket. That reign may soon end.

Over the hol­i­day week­end, As­traZeneca an­nounced its im­muno-on­col­o­gy drug Imfinzi has been grant­ed an FDA ‘pri­or­i­ty re­view’ for small-cell lung can­cer, or SCLC. The des­ig­na­tion comes on the heels of a 537-per­son tri­al show­ing the treat­ment helped pa­tients live a lit­tle un­der 3 months longer than un­der the stan­dard-of-care. A PDU­FA date was set for the first quar­ter of 2020.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER